Chemomab Therapeutics (CMMB) vs GT Biopharma (GTBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GT Biopharma (GTBP) has outperformed Chemomab Therapeutics (CMMB) over the past year, gaining 451.9% versus a loss of 60.3%. Over five years, CMMB leads with a -96.2% price change compared with -96.7% for GTBP. GT Biopharma is the larger company by market cap ($10.8 million vs $10.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMMB | GTBP |
|---|---|---|
| Share price | $1.39 | $5.96 |
| Market cap | $10.19M | $10.75M |
| 1-day change | +2.21% | -3.87% |
| YTD return | -15.76% | +659.24% |
| 1-year return | -60.29% | +451.85% |
| 5-year return | -96.18% | -96.72% |
| EPS (TTM) | $-1.04 | $-147.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.55 | $28.75 |
| 52-week low | $1.05 | $4.91 |
| Distance from 52-week high | -60.85% | -79.27% |
| Analyst consensus | none | none |
| Avg. price target upside | +259.71% | +1158.39% |
| Average volume | 118.53K | 55.55K |
| Shares outstanding | 7.33M | 1.80M |
| Employees | — | 1 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed CMMB by 512.1 percentage points over the past year.
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Healthcare · Biotechnology
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Healthcare · Biotechnology · 1 employees
CMMB vs GTBP FAQ
Which is bigger, Chemomab Therapeutics or GT Biopharma?
GT Biopharma (GTBP) is larger, with a market capitalization of $10.75M compared with $10.19M for Chemomab Therapeutics (CMMB).
Which stock has performed better over the past year, CMMB or GTBP?
GTBP returned +451.85% over the past 12 months, compared with -60.29% for CMMB (price return, excluding dividends). Past performance does not predict future results.
Are Chemomab Therapeutics and GT Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.